EVALUATION OF CYP2B6 INDUCTION AND PREDICTION OF CLINICAL DRUG-DRUG INTERACTIONS

被引：0
|
作者：
Fahmi, Odette A. [1 ]
机构：
[1] Pfizer, Pharmacokinet & Drug Metab, Groton, CT 06340 USA
来源：
DRUG METABOLISM AND PHARMACOKINETICS | 2017年 / 32卷 / 01期
关键词：
D O I：
10.1016/j.dmpk.2016.10.083
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
S62
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [31] Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model
    Almond, Lisa M.
    Mukadam, Sophie
    Gardner, Iain
    Okialda, Krystle
    Wong, Susan
    Hatley, Oliver
    Tay, Suzanne
    Rowland-Yeo, Karen
    Jamei, Masoud
    Rostami-Hodjegan, Amin
    Kenny, Jane R.
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (06) : 821 - 832
  • [32] Pregnane X Receptor: Prediction and Attenuation of Human CYP3A4 Enzyme Induction and Drug-Drug Interactions
    Sinz, Michael W.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 43, 2008, 43 : 405 - 418
  • [33] Quantitative Prediction of Drug-Drug Interactions Caused by CYP3A Induction Using Endogenous Biomarker 4β-Hydroxycholesterol
    Takubo, Hiroaki
    Taniguchi, Toshio
    Nomura, Yukihiro
    DRUG METABOLISM AND DISPOSITION, 2024, 52 (12) : 1438 - 1444
  • [34] CYP-mediated drug-drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome
    Cannady, Ellen A.
    Suico, Jeffrey G.
    Wang, Ming-Dauh
    Friedrich, Stuart
    Rehmel, Jessica R. F.
    Nicholls, Stephen J.
    Krueger, Kathryn A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (06) : 1388 - 1398
  • [35] Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: Potential drug interactions with bupropion
    Hesse, LM
    von Moltke, LL
    Shader, RI
    Greenblatt, DJ
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (02) : 100 - 102
  • [36] Quantitative prediction of CYP3A4 drug-drug interactions: Extending the strategy
    Galetin, A
    Hallifax, D
    Ito, K
    Houston, JB
    DRUG METABOLISM REVIEWS, 2003, 35 : 62 - 62
  • [37] Application of Different In Vitro Systems for Prediction of In Vivo Induction Drug-Drug Interactions
    Templeton, Ian E.
    Houston, J. Brian
    Galetin, Aleksandra
    DRUG METABOLISM REVIEWS, 2010, 42 : 114 - 114
  • [38] CYP2D6 "humanized" mice: A model for in vivo pharmacokinetics and drug-drug interactions
    Corchero, J
    Pimprale, S
    Krausz, K
    Gelboin, HV
    Gonzalez, J
    FASEB JOURNAL, 2000, 14 (08): : A1437 - A1437
  • [39] Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions
    Storelli, Flavia
    Matthey, Alain
    Lenglet, Sebastien
    Thomas, Aurelien
    Desmeules, Jules
    Daali, Youssef
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (01) : 148 - 157
  • [40] CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
    Metzger, Ingrid F.
    Dave, Nimita
    Kreutz, Yvonne
    Lu, Jessica B. L.
    Galinsky, Raymond E.
    Desta, Zeruesenay
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, : 657 - 666
12345